Skip to main content

Table 1 Baseline characteristics (n = 309, all male)

From: Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study

Characteristic

Value

Median (IQR) age, y

31 (26–42.5)

Median (IQR) BMI, kg/m2 a

22.15 (20.32–24.22)

Median (IQR) plasma glucose, mmol/L

5.30 (5.00–5.60)

Median (IQR) ALT, U/L

20 (14–28)

Median (IQR) CD4+ count, cells/μL

293 (192–418)

Median (IQR) CD8+ count, cells/μL

886 (628.5–1275)

Median (IQR) CD4/CD8 ratio

0.31 (0.20–0.45)

Geometric median (IQR) viral load, copies/mL b

4.67 (4.16–5.21)

Mean (SD) TC, mmol/L

3.72 ± 0.89

Mode of HIV acquisition c

 Hetero

48 (15.5%)

 MSM

243 (79.9%)

 Other

13 (4.2%)

Degree of education

 High school and below

126 (40.8%)

 University and above

106 (34.3%)

 No information

77 (24.9%)

TG borderline high

 No

280 (90.6%)

 Yes

29 (9.4%)

cART regimen

 3TC + TDF + EFV

238 (77.0%)

 3TC + AZT + EFV

22 (7.1%)

 3TC + TDF + LPV/r

31 (10.0%)

 Other regimens

18 (5.8%)

  1. Other regimens: 3TC + AZT + LPV/r, 3TC + ABC + LPV/r, 3TC + AZT + NVP, 3TC + ABC + EFV, 3TC + TDF + NVP, etc.
  2. Abbreviations: IQR Interquartile range, BMI Body mass index, SD Standard deviation, ALT Alanine aminotransferase, TC Total cholesterol, MSM Men who have sex with men, TG Triglyceride, 3TC Lamivudine, EFV Efavirenz, LPV/r Lopinavir/ritonavir, TDF Tenofovir disoproxil fumarate, NVP Nevirapine, AZT Zidovudine, ABC Abacavir, y Years old
  3. an = 307; b n = 308; c n = 304